Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2013

View Archived Issues

Novartis presents new dual function fusion proteins for diabetes

IMPACT Therapeutics describes novel anticancer agents

Researchers present preliminary results for a novel hepatitis B vaccine

Nerviano Medical Sciences prepares new serine/threonine-protein kinase inhibitors

Heptares Therapeutics achieves milestones in GPCR collaboration

Oxford BioTherapeutics and Boehringer Ingelheim to discover cancer antibody targets

BioLineRx starts enrollment in proof-of-concept phase I/II BL-8020 trial

Almac Discovery licenses ALM-201 to Shin Poong in South Korea

Forma Therapeutics and Celgene to advance drugs targeting protein homeostasis

Novartis' first quarter 2013 marked by regulatory approvals

New tablet formulation of posaconazole well tolerated in neutropenic patients

FGF-23 shows potential as a novel biomarker for myocardial pathologies

Kcentra approved in the U.S. for the reversal of anticoagulation

Early clinical results presented for ABT-288 in patients with schizophrenia

In vivo results described for novel enzyme replacement therapy for Pompe disease

Repros to collaborate with Northwestern University on phase II study of Proellex in breast cancer

GSK reflects on achievements of first quarter 2013

New orexin receptor antagonists patented by Actelion Pharmaceuticals

Trimel Pharmaceuticals submits NDA to FDA for CompleoTRT

Transition Therapeutics reports data from proof-of-concept study of TT-401

Indian team discloses new LTD4 receptor antagonists

Sandoz seeks marketing authorization of filgrastim biosimilar in Japan

GTx begins phase II study of enobosarm in metastatic breast cancer

Cyclacel Pharmaceuticals reports updated phase II data for sapacitabine in MDS

FDA assigns new PDUFA date to Alimera's resubmitted NDA for Iluvien

Sigma-Tau launches Cystaran in the U.S.

Navidea's Lymphoseek now available in the U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...